Amoéba : Publication of the 2021 Universal Registration Document

Amoéba announces the availability of the 2021 Universal Registration Document including the Annual Financial Report

Lyon (France), April 13, 2022 -8.30 am- AMOÉBA (FR0011051598 – ALMIB), producer of a biological
biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product
for plant protection, still in a development phase, announces that the 2021 Universal Registration
Document was filed with the French Financial Markets Authority (Autorité des marchés financiers AMF) on April 12, 2022 under number D.22-0280.

The 2021 Universal Registration Document includes:

  • the Annual Financial Report comprising the consolidated financial statements, the parent
    company financial statements, the management report and the related statutory auditors’
  • the Board of Directors’ corporate governance report.

The Universal Registration Document 2021 also presents the company’s activities, particularly in the
development of the biocidal and biocontrol applications and its research works. The organisation,
financial situation, results and prospects of Amoéba are also described in the Document.

The document may be viewed or downloaded on the company’s website
under section “Investors / financial documents/ Reference Document”. Copies of the Universal
Registration Document are also available at the company’s headquarters: 38, avenue des frères
Montgolfier, 69680 Chassieu, France.